GLUL and plasma cell myeloma: Especially, targeting the glutaminolysis pathway by inhibition of glutamine synthase (GS), cellular glutamine transporter (GLUTs) or oncogenes involved in the regulation of this metabolic pathway is a promising approach for heavily pretreated multiple myeloma patients [35].